AbbVie and Sosei Lead Slate of Early August R&D Deals

AbbVie and Sosei add neurological targets in new deal, TransCode and MD Anderson partner on RNA cancer therapies and Xenetic and VolitionRx unite to develop NETs-targeted therapies against cancer.

Related Keywords

Matt Barnes ,Xenetic Dnase ,Therapeuticsand Menarini Groupannounced ,Jeffrey Eisenberg ,Sendurai Mani ,Xenetic Biosciences ,Sosei Group Corporation ,Courtesy Of Abbvie Inc ,Abbvie Inc ,University Of Texas Md Anderson Cancer Centerto ,Sosei Add Neurological Targets ,New Deal ,Group Corporation ,Heptare Star ,Transcode Therapeutics ,Cancer Centerto ,Volitionrx Unite ,Targeted Therapies Against ,Neutrophil Extracellular Traps ,Menarini Partner ,Breast Cancer Combo ,Therapeuticsand Menarini Groupannounced Tuesday ,